Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Nurix Therapeutics (NRIX) Operating Income: 2019-2024

Historic Operating Income for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to -$213.0 million.

  • Nurix Therapeutics' Operating Income fell 67.34% to -$91.4 million in Q3 2025 from the same period last year, while for Aug 2025 it was -$267.2 million, marking a year-over-year decrease of 37.96%. This contributed to the annual value of -$213.0 million for FY2024, which is 37.38% down from last year.
  • Per Nurix Therapeutics' latest filing, its Operating Income stood at -$213.0 million for FY2024, which was down 37.38% from -$155.1 million recorded in FY2023.
  • Nurix Therapeutics' Operating Income's 5-year high stood at -$65.0 million during FY2020, with a 5-year trough of -$213.0 million in FY2024.
  • Moreover, its 3-year median value for Operating Income was -$183.9 million (2022), whereas its average is -$184.0 million.
  • As far as peak fluctuations go, Nurix Therapeutics' Operating Income crashed by 192.24% in 2020, and later increased by 15.67% in 2023.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Operating Income stood at -$65.0 million in 2020, then slumped by 81.41% to -$117.9 million in 2021, then slumped by 55.97% to -$183.9 million in 2022, then grew by 15.67% to -$155.1 million in 2023, then tumbled by 37.38% to -$213.0 million in 2024.